Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals episode artwork

EPISODE · Mar 11, 2022 · 58 MIN

Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals

from MIB Agents OsteoBites and osTEAo · host MIB Agents Osteosarcoma

This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. Matteo Trucco, MD is Director Children's Cancer Innovative Therapy Program Associate Staff, Peds Hematology-Oncology & BMT at Cleveland Clinic. He received his training in Pediatric Hematology/Oncology from John's Hopkins and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies.

Episode metadata supplied by the publisher feed · Published Mar 11, 2022

Embed this episode

NOW PLAYING

Osteosarcoma Q&A with OsteoWarriors sponsored by BTG Specialty Pharmaceuticals

0:00 58:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MIB Agents OsteoBites and osTEAo?

This episode is 58 minutes long.

When was this MIB Agents OsteoBites and osTEAo episode published?

This episode was published on March 11, 2022.

Can I download this MIB Agents OsteoBites and osTEAo episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!